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ABSTRACT | Purpose: To evaluate the response to sub-Tenon’s 
triamcinolone injection in patients with uveitis. Methods: We 
studied 28 eyes with macular edema associated with controlled 
uveitis. We administered sub-Tenon’s injection of triamcinolone 
and followed the patients for 180 days to analyze the positive 
effects (improvement of macular edema and visual acuity) and 
monitor the possible adverse effects. This prospective study 
was conducted at the Department of Ophthalmology, Hospital 
de Clínicas de Porto Alegre, Brazil. Results: We observed 
im provement in macular edema in 86% of patients. The mean 
central macular thickness at each time point of assessment 
was 432.22, 298.80, 286.37, 267.49, 253.87, and 253.49 μm 
at baseline (before sub-Tenon’s injection of triamcinolone), 15 
days after the procedure, at 30 days, at 60 days, at 90 days, 
and at 180 days, respectively. The mean reduction in retinal 
thickness was 30.8%, 33.7%, 38.11%, 41.2%, and 41.35% at 15, 
30, 60, 90, and 180 days of follow-up, respectively. Visual acuity 
also improved in 85.7% of patients, with a mean improvement 
of 1.36, 1.93, 2.23, 2.26, and 2.30 lines gained on the Early 
Treatment Diabetic Retinopathy Study chart at 15, 30, 60, 90, 
and 180 days of follow-up, respectively. No statistically significant 
increases in intraocular pressure and conjunctival abnormalities 
were caused by the procedure, and no other adverse effects 
were observed. Overall, the results of this study were similar 
to those described in the literature. Conclusions: Sub-Tenon’s 
injection of triamcinolone provides reduced macular thickness 
and improvement in visual acuity with no significant adverse 
effects and is therefore an effective and safe procedure for the 
treatment of sequelae of uveitis.
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RESUMO | Objetivos: Avaliar os efeitos da injeção subteno-
niana de triancinolona em pacientes com uveítes. Métodos: 
Foram incluídos na avaliação 28 olhos com edema macular 
associado à uveíte. Esses pacientes foram submetidos à injeção 
subtenoniana de triancinolona e acompanhados ao longo de 180 
dias, para analisar os efeitos em relação à melhora do edema 
macular, da acuidade visual e acompanhamento de possíveis 
efeitos adversos. Trata-se de um estudo prospectivo, realizado 
no Serviço de Oftalmologia do Hospital de Clínicas de Porto 
Alegre. Resultados: Foi verificada melhora do edema macular 
em 86% dos pacientes, sendo uma redução média da espessura 
retiniana de 30,8% aos 15 dias, 33,7% aos 30 dias, 38,11% aos 
60 dias, 41,2% aos 90 dias e 41,35% aos 180 dias de seguimento. 
Também foi observado melhora da acuidade visual em 85,7% 
dos pacientes e ganho de linhas na tabela de acuidade visual, 
sendo 1,36 linhas aos 15 dias de seguimento, 1,93 linhas aos 
30 dias, 2,23 linhas aos 60 dias, 2,26 linhas aos 90 dias e 2,30 
linhas aos 180 dias. Não houve significância estatística em relação 
ao aumento da pressão intraocular e às alterações conjuntivais 
causadas pelo procedimento, sem detecção de qualquer outro 
efeito colateral. Foi concluído que os resultados encontrados nesse 
estudo são similares aos descritos na literatura. Conclusões: A 
injeção subtenoniana de triancinolona é um procedimento eficaz 
e seguro para o tratamento das sequelas por quadros de uveítes, 
proporcionando redução da espessura macular e melhora da 
acuidade visual, sem relação com efeitos adversos significativos.
Descritores: Uveíte; Triancinolona; Injeções intravítreas; Edema 
macular; Cápsula de Tenon; Acuidade visual
INTRODUCTION
The term “uveitis” refers to any intraocular inflam-
mation affecting the uveal tract(1). Ocular involvement 
may lead to complications such as cataract, glaucoma, 
and macular edema-a late complication that, if left un-
treated for long, may result in irreversible visual loss(2,3).
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The aim of clinical treatment of uveitis is to control 
the inflammation and prevent ocular sequelae. Uveitis is 
treated mainly with corticosteroids(4,5). This class of me-
dication represents the first line of therapy in patients 
with non-infectious uveitis, and its effectiveness has 
stirred heated debate at uveitis treatment centers(6-8). 
The effect of triamcinolone in the treatment of macular 
edema secondary to diabetic or vascular retinopathy has 
been demonstrated in many studies. Few, however, have 
assessed its role in uveitis-related cases.
In selected cases of unilateral uveitis, the periocular 
administration of corticosteroids by, for instance, sub-Te-
non’s injection, is indicated either as an adjuvant to 
other routes of administration or where systemic corti-
costeroid therapy cannot be administered(4). Patients with 
infectious uveitis should not be administered periocular 
injections of corticosteroids in the absence of specific 
antimicrobial therapy, and corticosteroids should be 
prescribed with caution to patients with a history of increa-
sed intraocular pressure induced by corticosteroids(1).
The main advantage of sub-Tenon’s injection of cor-
ticosteroids, compared with other routes, is the large 
volume of medication it delivers to the ocular tissues for 
a longer period(9). Additional assurance of anatomically 
correct administration, improved drug availability, and 
a lower risk of adverse effects are provided by injection 
under operating microscope visualization(10).
The rare complications related to sub-Tenon’s in-
jection of triamcinolone include increased intraocular 
pressure, orbital infection, conjunctival ischemia(11) or 
ul ceration(12), an encapsulated triamcinolone cyst(13), and 
central serous chorioretinopathy(7). Despite these risks, 
sub-Tenon’s injection of triamcinolone is considered 
safe(6). In addition, a reduction in retinal thickness in cases 
of macular edema secondary to uveitis and improvement 
in visual acuity are associated with periocular triamcino-
lone therapy(7,14-16).
In this study, we aim to conduct a prospective eva-
luation of outcomes and complications arising from 
sub-Tenon’s injection of triamcinolone in patients with 
uveitis. Our primary objective is to evaluate the effect 
of sub-Tenon’s injection of triamcinolone in reducing 
central macular thickness in the presence of macular 
edema or subretinal fluid. Our secondary objectives are 
to assess changes in visual acuity and possible adverse 
effects, such as increased intraocular pressure and con-
junctival abnormalities.
METHODS
Study population
The study sample of 28 eyes of patients with con-
trolled uveitis was drawn from patients treated at the 
Outpatient Uveitis Clinic of the Department of Ophthal-
mology, Hospital de Clínicas de Porto Alegre, Brazil, all 
of whom had established indications for sub-Tenon’s 
injection of triamcinolone in accordance with ambula-
tory routine. The effect of injection of triamcinolone is 
local, affecting only the injected eye; we included in the 
study both eyes of patients with bilateral macular edema. 
The study included only patients aged 18 years or older, 
with macular edema or subretinal fluid in the macular 
region, based on optical coherence tomography (OCT). 
We excluded patients who had received periocular or 
intraocular injection of corticosteroids in the preceding 
6 months and patients on chronic systemic corticoste-
roid therapy (to prevent an additive effect of recent use 
of these medications); we also excluded patients with 
significant opacity of the intraocular media (such as a 
cataract or severe vitreitis)-potentially hindering the 
assessment of visual acuity-and patients who refused to 
provide written informed consent.
This prospective study was approved by the Research 
Ethics Committee of Hospital de Clínicas de Porto Alegre 
with judgment number 13-0532 and was conducted 
entirely at the Department of Ophthalmology of the afo-
rementioned hospital.
Patients
Patients who underwent sub-Tenon’s injection of triam-
cinolone under the guidance of an operating microscope 
were followed prospectively. Patients with infectious 
uveitis received specific antimicrobial therapy before 
pe riocular administration of corticosteroids. We admi-
nistered antibiotic treatment 15 days before injection in 
the case of tuberculosis uveitis and 3 days before in the 
case of toxoplasmosis uveitis. Patients with syphilis were 
injected simultaneously with the antibiotic treatment.
The same surgeon performed all procedures and also 
carried out follow-up and assessment of all patients 
throughout the study. Briefly, one drop of proxymetacaine 
hydrochloride induced topical anesthesia, the periocular 
region was prepped with povidone-iodine, an aseptic 
operating field was established with sterile drapes, 
and a blepharostat was put in place. Subconjunctival 
anesthesia was then induced by injection of 0.3 mL 2% 
lidocaine without vasoconstrictor into the superior tem-
poral quadrant of the bulbar conjunctiva. With the aid 
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of conjunctival scissors and forceps, this area was then 
opened and the sub-Tenon’s capsule space dissected (in 
the superior temporal direction), followed by injection 
of 1 mL triamcinolone acetonide (40 mg/mL), as poste-
riorly as possible, with the aid of a 24-gauge Abbocath®. 
We used a flexible cannula, which follows the curvature 
of the eyeball, thereby reducing the risk of Tenon’s cap-
sule, conjunctival, or scleral perforation. The procedure 
is demonstrated in figure 1.
We measured central macular thickness by OCT, 
per formed in a high-definition Cirrus scanner (Cirrus 
HD-OCT, Carl Zeiss), with images captured in a 512 
× 128 Macular Cube. We added the central macular 
thickness values of all patients and calculated the overall 
mean for each time point of assessment (before the 
procedure and 15, 30, 60, 90, and 180 days after the 
procedure). We then compared pre-procedural values 
to those measured during follow-up. We considered 
OCT-measured reductions in macular thickness of at 
least 100 μm compared with baseline (pre-procedural) 
values to be relevant.
We measured best-corrected visual acuity using an 
Early Treatment Diabetic Retinopathy Study (ETDRS) 
at 4 m (13 ft), scored as the logarithm of the minimum 
angle of resolution (logMAR). We added the visual acuity 
values of all patients and calculated the overall mean for 
each time point of assessment (before the procedure and 
15, 30, 60, 90, and 180 days after the procedure). We 
also calculated the overall mean gain in ETDRS chart 
lines for all patients at each time point of assessment. 
We then compared the baseline (pre-procedural) values 
for both parameters (visual acuity and ETDRS chart lines 
gained) with those obtained during follow-up.
We measured intraocular pressure with a Perkins to-
nometer. We added the intraocular pressure values of 
all eyes and the overall mean calculated for each time 
point of assessment (before the procedure and 15, 30, 
60, 90, and 180 days after the procedure). We then 
compared pre-procedural values with those measured 
during follow-up.
We also evaluated adverse effects, such as conjunc-
tival injury (presence of a conjunctival defect at the site 
of injection on slit-lamp biomicroscopy). We added the 
conjunctival defect area values of all patients and calcu-
lated and compared the overall mean for each time point 
(15, 30, 60, 90, and 180 days after the procedure). We 
also assessed the time to resolution of the conjunctival 
defect.
Statistical analysis
We calculated sample size in WINPEPI version 11.25. 
On the basis of the findings of a previous study by Adan 
et al.(17), which found a standard deviation of 66.5 μm 
before and 143.2 μm after the procedure, and consi-
dering a pre-post difference of 100 μm, 90% statistical 
power, a significance level of 0.05, and a correlation 
coefficient of 0.5, we estimated the minimum sample size 
to be 19 eyes.
We expressed quantitative variables as mean (standard 
deviation) or median and range of values (minimum and 
maximum) as appropriate, and we expressed qualitative 
variables as absolute and relative frequencies, using the 
generalized estimating equations method. We carried out 
all analyses in PASW Statistics, Version 18.0 (SPSS Inc.) 
at a significance level of 0.05.
RESULTS
The study, with a total of 19 patients, included 28 
eyes-17 (60%) from women and 11 (40%) from men; 15 
(53.5%) right eyes and 13 (46.5%) left eyes. The mean 
age of patients was 45 years (range, 21-74 years). Uveitis 
Figure 1. Sequence of sub-Tenon’s injection of triamcinolone: Subconjunctival anesthesia, opening of the bulbar conjunctiva, 
and triamcinolone injection with the aid of a 24G Abbocath® cannula.
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in the patients participating in the study had etiologies 
including seven cases (25%) of tuberculosis, four (14%) 
of toxoplasmosis, four (14%) of Behçet’s disease, three 
(11%) of sarcoidosis, three (11%) of idiopathic interme-
diate uveitis, three (11%) of traumatic uveitis, two (7%) 
of idiopathic anterior uveitis, and one each (3.5%) of 
syphilis and psoriatic arthritis.
Among the eyes examined, we considered four (14%) 
to be unresponsive to treatment, as there was no reduc-
tion in retinal thickness at a minimum of two time points 
of assessment, indicating other modes of treatment in 
such cases. We included these patients in calculations of 
results while they remained in the study and excluded 
them from the sample upon initiation of treatment other 
than the study intervention. Of these, two eyes with tu-
berculous uveitis were indicated for other treatment 30 
days after the procedure; one eye with uveitis secondary 
to Behçet’s disease was deemed unresponsive after 30 
days; and one eye with traumatic uveitis after 60 days.
In 86% of cases (24 eyes), central macular thickness 
improved progressively over time. The mean central 
macular thickness at each time point of assessment was: 
432.22, 298.80, 267.49, 253.87, and 253.49 µm at base-
line (before sub-Tenon’s injection of triamcinolone), 15 
days after the procedure, at 30 days, at 60 days, at 90 
days, and at 180 days, respectively. Results are shown 
in table 1 and figure 2.
The difference in mean central macular thickness 
in creased at all time points of assessment compared 
with the baseline measurement (before sub-Tenon’s in-
jection of triamcinolone). The mean reduction in central 
macular thickness was 133.43 μm (30.8%), 145.86 μm 
(33.7%), 164.73 μm (38.11%), 178.35 μm (41.2%), and 
178.73 μm (41.35%) after 15 days, after 30 days, after 
60 days, after 90 days, and after 180 days, respectively. 
All values were statistically significant (alpha <0.05). 
Results are shown in table 2. Figure 3 shows pre- and 
Table 2. Mean difference in central macular thickness (in μm) compared 
with baseline (pre-procedural) values
Time point of 
assessment (days)
Mean difference in 
macular thickness (μm)
Standard 
error
Alpha 
value
015 133.43 18.936 0.00
030 145.86 21.810 0.00
060 164.73 25.064 0.00
090 178.35 26.462 0.00
180 178.73 28.023 0.00
Figure 3. OCT scans of one patient before (A) and after (B) sub-Tenon’s 
triamcinolone injection.
A B
Table 1. Mean central macular thickness in μm
Time point of 
assessment 
(days)
Mean macular 
thickness 
(μm)
Standard 
error
Min (95% 
confidence 
interval)
Max (95% 
confidence 
interval)
000 432.22 31.172 371.13 493.32
015 298.80 18.701 262.14 335.45
030 286.37 22.290 242.68 330.05
060 267.49 16.311 235.52 299.46
090 253.87 14.097 226.24 281.50
180 253.49 17.014 220.15 286.84
Figure 2. Follow-up of mean central macular thickness in μm over 180 days.
post-treatment OCT findings in one of the patients in 
our study.
Visual acuity measurements also improved at all time 
points from baseline. On the ETDRS chart, measures of 
visual acuity range from 0 to 1, with 0 corresponding 
to the ability to read the smallest letters (best recorded 
visual acuity) and 1 corresponding to ability to read 
only the largest letters (worst recorded visual acuity). 
The mean ETDRS chart visual acuity (logMAR) was 
0.564, 0.432, 0.375, 0.359, 0.353, and 0.349 before 
sub-Tenon’s injection of triamcinolone, at 15 days after 
injection, at 30 days, at 60 days, at 90 days, and at 180 
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Figure 4. Follow-up of mean visual acuity (ETDRS chart, logMAR) over 
180 days.
Table 4. Mean lines gained on the ETDRS chart
Time point of 
assessment 
(days)
Mean lines 
gained on the 
ETDRS chart
Standard 
error
Min (95% 
confidence 
interval)
Max (95% 
confidence 
interval)
015 1.36 0.318 0.78 1.98
030 1.93 0.329 1.28 2.57
060 2.23 0.360 1.52 2.93
090 2.26 0.334 1.60 2.91
180 2.30 0.356 1.60 3.00
days post-procedure, respectively. Results are shown in 
table 3 and figure 4.
The number of lines gained on the ETDRS chart was 
progressively greater at all time points of assessment 
when compared with the baseline (before triamcinolone 
injection). On average, patients had gained 1.36 lines of 
acuity, 1.93, 2.23, 2.26, and 2.30 lines at 15, 30, 60, 90, 
and 180 days after the procedure, respectively. Results 
are shown in table 4.
There was no statistically significant increase in intrao-
cular pressure from baseline at any time point during 
follow-up. The mean intraocular pressure was 10.57, 
11.43, 13.07, 13.61, 12.32, and 12.24 mmHg prior to 
sub-Tenon’s injection of triamcinolone 15, 30, 60, 90, 
and 180 days after the procedure, respectively. Only 
three patients (10.7%) developed ocular hypertension 
requiring hypotensive eye drops. The measurements 
of increased intraocular pressure occurred at 30 days 
(26 mmHg), 60 days (44 mmHg), and 180 days (34 mmHg). 
These patients with increased intraocular pressure were 
treated with hypotensive eye drops for, respectively, 20, 
15, and 18 days.
We observed migration of the sub-Tenon’s triamci-
nolone deposit to the inferior region around the site of 
injection in only two of 28 eyes (7%), without statistical 
significance. In these two patients, on slit-lamp exami-
nation, the deposit remained visible until 90 days of 
follow-up but had been reabsorbed and was no longer 
visible at 180 days.
On slit-lamp examination, the visualized conjunctival 
defect at the injection site had a mean area of 1.14 mm² 
at 15 days and 0.32 mm² at 30 days. At 60 day assess-
ment, we were unable to detect any defect in any eye. 
There was no statistically significant difference in the 
area of conjunctival defect between time points.
DISCUSSION
In the treatment of complications of uveitis, such as 
ma cular edema and low visual acuity, sub-Tenon’s in-
jection of triamcinolone is a relatively simple procedure 
yielding good outcomes.
In this study, we observed that the administration 
of triamcinolone to patients with uveitis provides a 
significant reduction in central macular thickness and 
improves visual acuity. These effects were appreciable 
and sustained over a 6 month follow-up period, without 
any serious adverse effects. Our results were consistent 
with the findings of previous studies published in the 
literature.
Reduction in central macular thickness was progres-
sive over 6 months, demonstrating the persistence of 
the effect of triamcinolone over time. Furthermore, this 
reduction in macular thickness was detectable on first 
assessment, 15 days after injection, and persisted at 
6 month follow-up. In addition, the deposition of the 
corticosteroid in the sub-Tenon’s region was visible up 
to 90 days after the procedure in eyes in which triamci-
Table 3. Mean visual acuity measured on the ETDRS chart (logMAR)
Time point of 
assessment 
(days)
Meanvisual 
acuity 
(logMAR)
Standard 
error
Min (95% 
confidence 
interval)
Max (95% 
confidence 
interval)
000 0.564 0.0619 0.443 0.685
015 0.432 0.0588 0.317 0.547
030 0.375 0.0589 0.259 0.490
060 0.359 0.0600 0.241 0.477
090 0.353 0.0624 0.231 0.476
180 0.349 0.0651 0.222 0.477
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nolone migrated inferiorly to the site of injection. This 
demonstrates the ability of triamcinolone acetonide to 
form a deposit, resulting in prolonged effects.
In patients with uveitis and macular edema, visual 
acuity is also improved with sub-Tenon’s injection of 
triamcinolone. Mean visual acuity, already improved 
at first assessment (15 days after injection), continued 
to increase progressively thereafter over the 6 month 
follow-up period. This beneficial effect on visual acuity 
was also evident through the number of lines gained, 
which also increased progressively at each time point 
of assessment.
In this study, adverse effects-such as increased intrao-
cular pressure and conjunctival abnormalities-were not 
significantly prevalent. This indicates that sub-Tenon’s 
injection of triamcinolone is a safe procedure, if per-
formed with the proper technique and with periodic 
patient follow-up.
In a retrospective case series, Liu et al. evaluated 
37 eyes with uveitis-associated macular edema over 
a 6 month period. One month after subconjunctival 
injection of triamcinolone, the mean central macular 
thickness had decreased from 498.9 μm at baseline 
assessment to 392.4 μm. Visual acuity had also impro-
ved in 54.1% of cases, from an average of 0.45 logMAR 
on initial assessment to 0.33 logMAR at the end of the 
study. An increased intraocular pressure (>21 mmHg) 
occurred in nine eyes (24.3%)(13).
In a retrospective study, Bleriot et al. treated 31 eyes 
with uveitis-associated macular edema with subcon-
junctival injection of triamcinolone, followed up over 12 
months. The mean visual acuity was 0.36, 0.23, and 0.24 
logMAR on initial assessment, at 3 month follow-up, and 
at 12 month follow-up, respectively. The mean central 
macular thickness measured on OCT was 444 μm at initial 
assessment and 355 μm at 3 month follow-up. There was 
no significant increase in intraocular pressure(18).
In a 6-month prospective study, Tanner et al. evalua-
ted the effects of sub-Tenon’s injection of triamcinolone 
in patients with posterior and intermediate uveitis. They 
observed improvement in visual acuity in 89.2% of cases 
and increased intraocular pressure in 14%(19).
Yoshikawa et al. performed sub-Tenon’s injection of 
triamcinolone in 39 eyes with uveitis-associated macular 
edema. At least two lines in visual acuity were gained in 
56.4% of treated eyes. However, there was no improve-
ment in visual acuity in 28.2% of eyes. Only one patient 
(2.5%) developed glaucoma(20).
In a retrospective study, Okada et al. evaluated 51 
eyes of patients with posterior uveitis who had received 
sub-Tenon’s injections of triamcinolone. Overall, 82% 
of patients exhibited a reduction in macular edema, and 
improvements in visual acuity were detected as soon as 
the first month of follow-up; 27% of patients, however, 
developed increased intraocular pressure(21).
Sub-Tenon’s injection of triamcinolone is beneficial 
for patients with complications of uveitis, as this proce-
dure reduces retinal thickness in patients with cystoid 
macular edema secondary to uveitis. Improvement can 
be observed as early as 15 days after injection and is sus-
tained for at least 180 days thereafter. In terms of visual 
acuity, triamcinolone injection allowed progressive im-
provement in the number of lines gained on the ETDRS 
chart as well as in mean visual acuity (logMAR); this im-
provement was perceptible shortly after the procedure 
and also persisted for at least 6 months.
It is a safe procedure, besides the possibility of intrao-
cular hypertension, and is not associated with severe 
conjunctival injury.
Our study did not refer to the development of cata-
racts-a frequent complication-because of the long period 
of follow-up that would have been necessary.
In short, we found sub-Tenon’s injection of triamcino-
lone to be an effective and safe procedure for reducing 
central macular thickness in patients with cystoid macular 
edema secondary to uveitis and also to improve visual 
acuity in these patients.
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